Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two essential parasite processes. Atovaquone blocks the mitochondrial electron transport chain, halting energy production, while proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme needed for DNA synthesis. Together they stop parasite replication.

The dosage of Malarone is individualized by the prescribing clinician based on factors such as the patient’s age, body weight, the indication (prophylaxis versus treatment), and any underlying health conditions. Only a qualified healthcare provider should set the exact regimen.

Safety data for Malarone during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Malarone, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone offers a convenient once‑daily oral regimen and combines two mechanisms of action, which can reduce the risk of resistance compared with single‑agent therapies such as chloroquine. It is generally well‑tolerated, but alternatives like doxycycline or mefloquine may be preferred in specific clinical scenarios or based on patient tolerance.

Malarone tablets should be stored at ambient temperature below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Malarone is taken by mouth with food or a milky drink to enhance absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area, continued daily throughout exposure, and taken for 7 days after leaving the area. For treatment, the full prescribed course should be completed.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, significant liver injury, and hematologic abnormalities like neutropenia or anemia. Any signs of rash, jaundice, unexplained fever, or unusual bleeding should prompt immediate medical evaluation.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Patients with severe renal or hepatic impairment should avoid use unless specifically directed by a physician, and it should not be used in pregnant women unless the benefits outweigh the risks.